Role of DNMT3B Genetic Polymorphism (rs1569686) in Predicting Overall Survival and Clinic-Pathological Outcomes in Lung Cancer Patients Treated with Platinum Based Doublet Chemotherapy

Abstract

ABSTARCT Title: Role of DNMT3B gene in predicting overall survival and clinic-pathological outcomes in lung cancer patients treated with doublet chemotherapy. DNA methylation is one of the important epigenetic mechanisms. Any alterations in the methylation mechanism can affect the process of transcription. Basically DNA methylation is a heritable marker which involves the covalent transfer of a methyl group to the C-5 position of the cytosine ring of DNA by DNA methyltransferases (DNMTs). DNMT3B is essential for the maintenance and establishment of DNA methylation patterns and required for genome-wide de-novo methylation during development. Objectives: To investigate the role of DNMT3B (-579 G>T, rs1569686) polymorphism in modulating the overall survival and clinical outcomes of lung cancer patients. Results: Lung cancer patients with this polymorphism of DNMT3B (-579G>T, rs1569686) found to have significant association in overall survival (HR’=1.45; 95% CI=1.02-2.08; P=0.03). Significant association was also found with overall survival in SCLC patients (HR’=16.27; 95%CI=1.13-232.4; P=0.04) and in SQCC patients (HR’=0.40; 95% CI=0.19-0.86; P=0.01). Conclusion: Therefore, it is evident that this polymorphism is capable for predicting the overall survival of heterozygous patients and also, shows some interesting relationship of this genotype with overall survival of SCLC and SQCC patients.